SuperworthGreenland Mines EPS GRML
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$12.50
- Latest quarter, Q2 FY26
- −$1.50
- Fiscal year 2025
- −$13.50
Greenland Mines' earnings per share was −$12.50 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.50.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$13.50 | n/a |
| FY2024 | −$16.50 | n/a |
| FY2023 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.50 | n/a | −$12.50 | |
| Q1 FY26 | −$7.50 | n/a | −$17.00 | |
| Q4 FY25 | −$1.00 | n/a | −$13.50 | |
| Q3 FY25 | −$2.50 | n/a | −$16.50 | |
| Q2 FY25 | −$6.00 | n/a | −$23.00 | |
| Q1 FY25 | −$4.00 | n/a | −$18.50 | |
| Q4 FY24 | −$4.00 | n/a | −$16.50 | |
| Q3 FY24 | −$9.00 | n/a | −$13.00 | |
| Q2 FY24 | −$1.50 | n/a | −$4.50 | |
| Q1 FY24 | −$2.00 | n/a | n/a | |
| Q4 FY23 | −$0.50 | n/a | n/a | |
| Q3 FY23 | −$0.50 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Greenland Mines' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GRMLGreenland Mines | −$12.50 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Greenland Mines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.